Berobenatide
A Study to Learn About the Study Medicine Called PF-08653944 Taken Once-Weekly Compared to Placebo in Chinese Adults With Overweight or Obesity
Pfizer · Phase 3 · Recruiting · Enrollment 300
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Berobenatide Medium Maintenance Dose | n/r | n/r | n/r | n/r |
| Placebo Matched to Low-Dose Berobenatide | n/r | n/r | n/r | n/r |
| Berobenatide Low Maintenance Dose | n/r | n/r | n/r | n/r |
| Berobenatide High Maintenance Dose | n/r | n/r | n/r | n/r |
| Placebo Matched to Medium-Dose Berobenatide | n/r | n/r | n/r | n/r |
| Placebo Matched to High-Dose Berobenatide | n/r | n/r | n/r | n/r |
Not shown
- Berobenatide Medium Maintenance Dose: endpoint not reported
- Placebo Matched to Low-Dose Berobenatide: endpoint not reported
- Berobenatide Low Maintenance Dose: endpoint not reported
- Berobenatide High Maintenance Dose: endpoint not reported
- Placebo Matched to Medium-Dose Berobenatide: endpoint not reported
- Placebo Matched to High-Dose Berobenatide: endpoint not reported